Hikma Pharmaceuticals Plc Hikma and GSK agree to cease potential acquisition (9932R)
11 Marzo 2021 - 02:36PM
UK Regulatory
TIDMHIK
RNS Number : 9932R
Hikma Pharmaceuticals Plc
11 March 2021
London, 11 March 2021 - On 26 January 2021, Hikma
Pharmaceuticals PLC (Hikma) announced that it had entered into a
non-binding term sheet with GlaxoSmithKline PLC (GSK) for the
purposes of potentially acquiring GSK's pharmaceutical and consumer
businesses in Egypt and its pharmaceutical business in Tunisia (the
Proposed Transaction).
Hikma today confirms that both companies have agreed to cease
discussions regarding the Proposed Transaction and, accordingly,
Hikma will not be launching a Mandatory Tender Offer process to
acquire the shares in GlaxoSmithKline SAE Egypt.
- ENDS -
Enquiries
Hikma Pharmaceuticals PLC
Susan Ringdal +44 (0)20 7399 2760/ +44 7776
EVP, Strategic Planning and Global Affairs 477050
Layan Kalisse uk-investors@hikma.uk.com
Investor Relations Analyst
+44 (0)20 7399 2788 / +44 (0)7970
709912
Mona Abdallah +962 7 96777710
Communication Director - MENA mena_communications@hikma.com
Teneo (Press):
Charles Armitstead/ Camilla Cunningham +44 (0)7703 330 269/ +44
(0)7464 982 426
About Hikma
(LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated BBB-/stable
S&P, BBB-/stable Fitch and Ba1/stable Moody's)
Hikma helps put better health within reach every day for
millions of people in more than 50 countries around the world. For
more than 40 years, we've been creating high-quality medicines and
making them accessible to the people who need them. Headquartered
in the UK, we are a global company with a local presence across the
United States (US), the Middle East and North Africa (MENA) and
Europe, and we use our unique insight and expertise to transform
cutting-edge science into innovative solutions that transform
people's lives. We're committed to our customers, and the people
they care for, and by thinking creatively and acting practically,
we provide them with a broad range of branded and non-branded
generic medicines. Together, our 8,600 colleagues are helping to
shape a healthier world that enriches all our communities. We are a
leading licensing partner, and through our venture capital arm, are
helping bring innovative health technologies to people around the
world. For more information, please visit: www.hikma.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCJBMJTMTJBBJB
(END) Dow Jones Newswires
March 11, 2021 08:36 ET (13:36 GMT)
Grafico Azioni Hikma Pharmaceuticals (LSE:HIK)
Storico
Da Feb 2024 a Mar 2024
Grafico Azioni Hikma Pharmaceuticals (LSE:HIK)
Storico
Da Mar 2023 a Mar 2024